APW
PBYI icon

Aventura Private Wealth’s Puma Biotechnology PBYI Stock Holding History

Aventura Private Wealth’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-100
Closed -$305 – 806
2024
Q4 		$305 Buy
+100
New +$291 ﹤0.01% 716

Other funds holding PBYI

ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Aventura Private Wealth's PBYI Position: Q1 2025 in Review

Aventura Private Wealth sold out of Puma Biotechnology (PBYI) in Q1 2025, closing a stake of 100 shares — an estimated $305 sold.

Aventura Private Wealth first reported a position in PBYI in Q4 2024 and held it in 1 quarter. The position peaked at $305 in Q4 2024. 116 funds tracked by Wall St. Rank hold PBYI as of Q1 2025.

  • Aventura Private Wealth reported no remaining Puma Biotechnology position as of Q1 2025 after selling out during the quarter.
  • Aventura Private Wealth sold 100 Puma Biotechnology shares in Q1 2025, an estimated $305.
  • Aventura Private Wealth first reported a position in Puma Biotechnology in Q4 2024 and held it in 1 quarter.
  • Aventura Private Wealth's Puma Biotechnology position peaked at $305 in Q4 2024.
  • 116 funds tracked by Wall St. Rank held Puma Biotechnology as of Q1 2025.

Based on Aventura Private Wealth's 13F filing for Q1 2025, filed 7 Jan 2026.